Nursing Elites

1. When caring for a client prescribed Digoxin, which finding should the nurse monitor to assess for potential toxicity?

• A. Bradycardia
• B. Hypertension
• C. Hypoglycemia
• D. Hypercalcemia

Correct answer: A

Rationale: Bradycardia is a common sign of Digoxin toxicity. Digoxin, a cardiac glycoside, can lead to toxic effects such as bradycardia, which is a slow heart rate. Therefore, the nurse should closely monitor the client's heart rate for any significant decreases, as this could indicate Digoxin toxicity and prompt further intervention. Choices B, C, and D are incorrect because Digoxin toxicity typically presents with bradycardia, not hypertension, hypoglycemia, or hypercalcemia.

2. Why should the nitrate patch be off for 8 hours per day?

• A. “There is no reason to take the patch off each day.”
• B. “The patch can be addictive; leaving it off reduces the addiction.”
• C. “You should only leave the patch off for 15 minutes.”
• D. “Leaving the patch off for 8 hours per day helps to delay the development of tolerance.”

Correct answer: D

Rationale: Removing the nitrate patch for 8 hours each day is essential to prevent the body from developing tolerance to the medication. By allowing the body to have a drug-free period, the effectiveness of the medication is maintained over time. This practice helps in ensuring that the nitrate patch continues to provide its intended therapeutic effects without diminishing its efficacy. Therefore, it is important for the client to adhere to the prescribed schedule of removing the patch for 8 hours daily to optimize the treatment outcomes.

3. During a unit of whole blood transfusion, a client develops a cough, shortness of breath, elevated blood pressure, and distended neck veins. The healthcare professional should anticipate a prescription for which of the following medications?

• A. Epinephrine
• B. Lorazepam
• C. Furosemide
• D. Diphenhydramine

Correct answer: C

Rationale: In the scenario described, the client is exhibiting signs of fluid overload, which can occur during blood transfusion. Furosemide, a loop diuretic, is commonly prescribed in such situations to help relieve manifestations of circulatory overload by promoting diuresis and reducing fluid volume. Therefore, the correct choice is C - Furosemide. Epinephrine (Choice A) is not indicated for fluid overload but for severe allergic reactions. Lorazepam (Choice B) is a benzodiazepine used for anxiety or sedation, not for fluid overload. Diphenhydramine (Choice D) is an antihistamine often used for allergic reactions, not for fluid overload.

4. A client has a new prescription for Etravirine, an NNRTI. Which of the following statements should the nurse include in teaching the client?

• A. Take this medication with food.
• B. Take this medication on an empty stomach.
• C. Take this medication at the same time every day.
• D. Take this medication at bedtime to prevent drowsiness.

Correct answer: C

Rationale: The correct statement the nurse should include in teaching the client is to take Etravirine at the same time every day. This ensures consistent blood levels and effectiveness of the medication. Consistent timing is essential to achieve optimal therapeutic effects and avoid missing doses. Choices A and B are incorrect because Etravirine should not necessarily be taken with or without food; it is more important to take it consistently. Choice D is incorrect as there is no need to take Etravirine at bedtime to prevent drowsiness.

5. A client has a new prescription for Valsartan. Which of the following adverse effects should the nurse monitor?

• A. Hyperkalemia
• B. Hypoglycemia
• C. Bradycardia
• D. Hypercalcemia

Correct answer: A

Rationale: Corrected Rationale: Valsartan is an angiotensin II receptor blocker (ARB) that can cause hyperkalemia by affecting the renin-angiotensin-aldosterone system. The nurse should closely monitor the client's potassium levels due to the risk of hyperkalemia, which can lead to serious cardiac complications. Choice B, hypoglycemia, is not a common adverse effect of Valsartan. Choice C, bradycardia, is not directly associated with Valsartan use. Choice D, hypercalcemia, is not a typical adverse effect of Valsartan.

Similar Questions